We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Neurology

Journal Scan / Research · September 11, 2021

Nonimmunogenic Recombinant Staphylokinase Noninferior to Alteplase for Acute Stroke

The Lancet Neurology


Additional Info

The Lancet Neurology
Non-Immunogenic Recombinant Staphylokinase Versus Alteplase for Patients With Acute Ischaemic Stroke 4.5 h After Symptom Onset in Russia (FRIDA): A Randomised, Open Label, Multicentre, Parallel-Group, Non-Inferiority Trial
Lancet Neurol 2021 Sep 01;20(9)721-728, EI Gusev, MY Martynov, AA Nikonov, NA Shamalov, MP Semenov, EA Gerasimets, EB Yarovaya, AM Semenov, AI Archakov, SS Markin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading